AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
225.37
-2.31 (-1.01%)
At close: Mar 12, 2026, 4:00 PM EDT
225.68
+0.31 (0.14%)
After-hours: Mar 12, 2026, 5:24 PM EDT
AbbVie Employees
AbbVie had 57,000 employees as of December 31, 2025. The number of employees increased by 2,000 or 3.64% compared to the previous year.
Employees
57,000
Change (1Y)
2,000
Growth (1Y)
3.64%
Revenue / Employee
$1,072,982
Profits / Employee
$73,439
Market Cap
398.49B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 57,000 | 2,000 | 3.64% |
| Dec 31, 2024 | 55,000 | 5,000 | 10.00% |
| Jan 31, 2024 | 50,000 | 0 | - |
| Jan 31, 2023 | 50,000 | 0 | - |
| Jan 31, 2022 | 50,000 | 3,000 | 6.38% |
| Jan 31, 2021 | 47,000 | 17,000 | 56.67% |
| Jan 31, 2020 | 30,000 | 0 | - |
| Jan 31, 2019 | 30,000 | 1,000 | 3.45% |
| Jan 31, 2018 | 29,000 | -1,000 | -3.33% |
| Jan 31, 2017 | 30,000 | 2,000 | 7.14% |
| Jan 31, 2016 | 28,000 | 2,000 | 7.69% |
| Jan 31, 2015 | 26,000 | 1,000 | 4.00% |
| Jan 31, 2014 | 25,000 | 3,500 | 16.28% |
| Jan 31, 2013 | 21,500 | 0 | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| Eli Lilly and Company | 50,000 |
ABBV News
- 1 day ago - Harbor Health Care ETF Q4 2025 Portfolio Review - Seeking Alpha
- 2 days ago - AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 3 days ago - AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults - PRNewsWire
- 8 days ago - AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 9 days ago - February Dividends With 4 Raises: 1.6% Up To 14.5% - Seeking Alpha
- 9 days ago - AbbVie to Present at the Leerink Partners Global Healthcare Conference - PRNewsWire
- 10 days ago - AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease - PRNewsWire
- 10 days ago - The High Dividend Yield Bull Market: 3 Compelling 6% Yields - Seeking Alpha